Earningsreport

Q3/2024 9/30/2024 EPS -0.430 ZacksConsensus -0.370 ActVsEst (0.060) - Miss

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com